California State Teachers Retirement System Buys 10,196,347 Shares of Globus Medical, Inc. $GMED

Key Points

• California State Teachers Retirement System dramatically increased its Globus Medical stake by purchasing 10.2 million shares, bringing its ownership to approximately 7.69% of the company, valued at $815.9 million.
• Globus Medical reported quarterly EPS of $1.34, beating estimates of $1.10, while revenue rose 5.9% year over year to $789.6 million. The company issued fiscal 2026 EPS guidance of $4.95–$5.05.
• Analysts maintain a consensus “Moderate Buy” rating with a $101.77 average price target, although several firms recently lowered their targets. GMED shares opened at $74.21, well below the consensus target.

California State Teachers Retirement System increased its position in shares of Globus Medical, Inc. (NYSE:GMED - Free Report) by 7,827.7% in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 10,326,607 shares of the medical device company's stock after purchasing an additional 10,196,347 shares during the quarter. California State Teachers Retirement System owned approximately 7.69% of Globus Medical worth $815,905,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. AQR Capital Management LLC grew its holdings in Globus Medical by 45.9% during the 1st quarter. AQR Capital Management LLC now owns 22,510 shares of the medical device company's stock worth $1,622,000 after acquiring an additional 7,086 shares during the last quarter. Integrated Wealth Concepts LLC lifted its position in shares of Globus Medical by 33.0% during the first quarter. Integrated Wealth Concepts LLC now owns 4,375 shares of the medical device company's stock worth $320,000 after purchasing an additional 1,085 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in shares of Globus Medical by 38.6% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 30,649 shares of the medical device company's stock worth $2,228,000 after purchasing an additional 8,540 shares in the last quarter. Jones Financial Companies Lllp grew its stake in shares of Globus Medical by 237.3% during the first quarter. Jones Financial Companies Lllp now owns 850 shares of the medical device company's stock valued at $62,000 after purchasing an additional 598 shares during the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its holdings in shares of Globus Medical by 8.8% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 347,527 shares of the medical device company's stock valued at $25,439,000 after purchasing an additional 28,027 shares in the last quarter. 95.16% of the stock is owned by institutional investors.

Insider Transactions at Globus Medical

In other Globus Medical news, Director Stephen Zarrilli sold 25,000 shares of Globus Medical stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $87.04, for a total transaction of $2,176,000.00. Following the completion of the transaction, the director directly owned 25,000 shares of the company's stock, valued at $2,176,000. The trade was a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 18.38% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

GMED has been the topic of a number of recent research reports. Wells Fargo & Company decreased their price objective on Globus Medical from $103.00 to $99.00 and set an "overweight" rating on the stock in a research report on Friday, August 7th. Stifel Nicolaus cut their price target on Globus Medical from $95.00 to $80.00 and set a "hold" rating on the stock in a research note on Wednesday, July 8th. Piper Sandler cut their price target on Globus Medical from $115.00 to $100.00 and set an "overweight" rating on the stock in a research note on Monday, June 15th. Royal Bank Of Canada decreased their price target on Globus Medical from $120.00 to $115.00 and set an "outperform" rating on the stock in a report on Monday, July 13th. Finally, UBS Group initiated coverage on Globus Medical in a research report on Tuesday, July 28th. They issued a "neutral" rating and a $82.00 price objective for the company. Three equities research analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and five have given a Hold rating to the company's stock. According to MarketBeat.com, Globus Medical has a consensus rating of "Moderate Buy" and a consensus target price of $101.77.

Globus Medical Price Performance

Shares of Globus Medical stock opened at $74.21 on Monday. The firm has a market cap of $9.96 billion, a price-to-earnings ratio of 18.98, a price-to-earnings-growth ratio of 1.19 and a beta of 0.95. The stock's 50-day moving average is $80.40 and its 200-day moving average is $83.75. Globus Medical, Inc. has a one year low of $54.15 and a one year high of $101.40.

Globus Medical (NYSE:GMED - Get Free Report) last issued its quarterly earnings results on Thursday, August 6th. The medical device company reported $1.34 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.10 by $0.24. Globus Medical had a net margin of 17.02% and a return on equity of 14.57%. The firm had revenue of $789.61 million for the quarter, compared to analyst estimates of $782.88 million. During the same period in the previous year, the business earned $0.86 EPS. The company's revenue was up 5.9% compared to the same quarter last year. Globus Medical has set its FY 2026 guidance at 4.950-5.050 EPS. On average, equities analysts expect that Globus Medical, Inc. will post 4.99 EPS for the current year.

About Globus Medical

Globus Medical, Inc NYSE: GMED is a medical device company that develops, manufactures and markets musculoskeletal solutions for surgeons, hospitals and patients. Its primary focus is spinal surgery, supported by a portfolio of implants, instruments and enabling technologies designed to assist with procedures involving the cervical, thoracic and lumbar spine.

The company's products include spinal fusion systems, interbody devices, deformity correction systems, biologics and surgical instruments.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.